ArticleBMJ oncology2023

NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08).

Jérôme Fayette et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.